Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
aug  august  cannabis  company  financial results  financial  marketwired aug  marketwired august  marketwired  quarter  results 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Thu, 17 Aug 2017 00:23:28 EDT

Copyright: Copyright: (C) Marketwired
 



Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

Wed, 16 Aug 2017 23:52:45 EDT

MONTRÉAL, QUÉBEC--(Marketwired - Aug. 16, 2017) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the following individuals were elected as directors of Acasti Pharma Inc. ("Acasti" or the "Corporation") at its Annual and Special Meeting of Shareholders, held in Montreal, Canada on August 15, 2017 (the "AGM"): Janelle D'Alvise, Jean-Marie (John) Canan, Roderick N. Carter, Richard P. Schottenfeld and Katherine Crewe. Immediately prior to the AGM, Pierre Fitzgibbon and James S. Hamilton, who had been candidates for election to the Board and listed in the management proxy circular dated July 13, 2017, withdrew their candidacies for election to the Board. Mr. Fitzgibbon's withdrawal followed his resignation from the board of directors of Neptune Technology & Bioressources Inc. ("Neptune"). At the AGM, Neptune nominated Richard P. Schottenfeld and Katherine Crewe in their place. The detailed results of the vote for the election of directors are set out below:




Patients Are Not the #1 Target for Social Media & Other Digital Marketing Strategies, New Study Finds

Wed, 16 Aug 2017 17:42:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - August 16, 2017) - A new study of pharmaceutical marketing teams found that the primary digital strategy priority is to educate and communicate with physicians, making communication with patients across digital platforms a secondary priority.




Avadim Technologies Named to the Inc. 500 List of Fastest-Growing Private Companies in America for the Second Consecutive Year

Wed, 16 Aug 2017 13:42:42 EDT

Avadim Listed as the 13th Fastest Growing Company in U.S. Health Sector and 2nd Overall in North Carolina; Avadim Ranks No. 162 on the 2017 Inc. 500 List with Three-Year Sales Growth of 2,538%




Pressure BioSciences, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update

Wed, 16 Aug 2017 12:13:58 EDT

Total Revenue, Products & Services Revenue, Instrument Sales & Grant Activity All Increased Q/Q; New Five Person Field Sales Team Now Complete with Two Recent Additional Hires

Investor Conference Call Scheduled for Wednesday, August 16, 2017 at 4:30 PM EDT




Easton Pharmaceuticals Announces Advancing $575,000 Payment Towards Closed Agreement With Alliance Group For The Cultivation Of Medical / Recreational Marijuana For Canada and Other Revenue Producing Businesses

Wed, 16 Aug 2017 10:34:37 EDT

TORONTO, ON--(Marketwired - Aug 16, 2017) - Easton Pharmaceuticals, Inc. (OTC PINK: EAPH), pursuant to its previously announced closing agreement with Canadian based -- Alliance Group -- Easton has advanced $575,000 towards its acquired interest in 45 acres of a 135-acre fully owned parcel of land for the cultivation, production and sale of medical / recreational marijuana to the cannabis industry and towards other revenue producing businesses.




MediXall Group, Inc. Provider Network Is Now Over 3,000 Members

Wed, 16 Aug 2017 10:08:23 EDT

MediXall Group is growing Provider Network -- preparing to offer a full suite of unique medical financing solutions to Network Members




Cannabis Science and Free Spirit Organics Native American Corporation (FSO NAC) Begin Harvesting Approximately 60 Acres of its 250-Acre Industrial Hemp Project on San Joaquin Sovereign Tribal Fee Land MBS, California

Wed, 16 Aug 2017 09:16:58 EDT

IRVINE, CA--(Marketwired - Aug 16, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, and Free Spirit Organics Native American Corporation (FSO NAC), announce the initial harvesting of approximately 60 acres of industrial hemp on San Joaquin Sovereign Tribal Fee land MBS, California. The 2017 CBIS/FSO NAC MBS001 harvesting is a two-phase project, the first phase of the harvesting will be approximately 15-acres that is underway now, it is expected to be completed by the end of this month. Phase two will be the remaining 45 acres and is expected to be completed by the end of September 2017.




First Harvest Launches Ufly420 for On-Demand Legal Cannabis Delivery

Wed, 16 Aug 2017 08:30:00 EDT

Enabling Connectivity Technology




Sipp Industries Signs Letter of Intent to Acquire Minority Stake in Wanderport Corporation, Enhancing Product Selection

Wed, 16 Aug 2017 08:30:00 EDT

Sipp Industries Diversifies Specialty Hemp Beverage Line with the Addition of Sapa's Premium Coffee Blends to its Portfolio of Top Quality Hemp Beverages




420JobSearch.com and ZipRecruiter.com Announce Partnership, Broadening Jobs Offered

Wed, 16 Aug 2017 08:00:00 EDT

HENDERSON, NV--(Marketwired - Aug 16, 2017) - mCig, Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis and vape markets with innovative products, technologies, and services is pleased to announce a partnership between its Job Search Portal (420JobSearch.com) and ZipRecruiter.com420jobsearch.com recently entered into an agreement with ziprecruiter.com to enable both companies to broaden the scope of jobs available to job seekers. 




LiveWire Ergogenics, Inc. Announces Analyst Coverage Initiated By Stock Watch Index

Wed, 16 Aug 2017 08:00:00 EDT

ANAHEIM, CA--(Marketwired - Aug 16, 2017) - LiveWire Ergogenics, Inc. (OTC PINK: LVVV), a company focused on research partnerships, product development and commercialization of cannabinoid-based products, is pleased to announce that Stock Watch Index has initiated equity analyst coverage on LVVV.




Moleculin Acquires Active Drug Compound for the Treatment of Brain Cancer

Wed, 16 Aug 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - August 16, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced it has acquired WP1122 active drug compound it plans to study for the treatment of brain tumors.




Overcome Pharma Data Challenges to Improve Outcomes and Operations: Lessons Learned from Other Industries, New Webinar Hosted by Xtalks

Wed, 16 Aug 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - August 16, 2017) - In a live session on Friday, September 8, 2017, industry expert Gary Palgon, Vice President of Healthcare and Life Sciences Solutions at Liaison Technologies will examine what the future holds for the healthcare and pharma ecosystems making the digital transformation, leveraging big data - including new and existing data sources - and using technologies to enhance clinical and operations processes.




Why Making Every Product Truly Unique is the Key to Modern Brand Protection

Wed, 16 Aug 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - August 16, 2017) - In this live webinar, Jim Sinisgalli, Director of Product Management and Brand Protection at Systech will outline their ability to create trusted uniqueness in every product, and how this idea is central to a modern approach to brand protection.




Solvents, Polymers & Cyclones -- Bioavailability Enhancement through Spray Dried Dispersions

Wed, 16 Aug 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - August 16, 2017) - In an Xtalks webinar scheduled for Thursday, September 7, 2017 at 11am EDT (4pm BSK/UK), industry experts Stephie Lee, Associate Scientist at Catalent and Eric Gorman, Research Scientist II at Gilead Sciences, will introduce key spray dried dispersion development considerations allowing for identification of a stable prototype that will enhance and sustain in-vivo drug solubility. The discussion will include spray dried dispersion formulation development and early phase considerations for finished dose development.




Corix Bioscience, Inc. Signs Major Sales Agreement for up to 22,000 Pounds of Hemp per Month

Wed, 16 Aug 2017 06:00:00 EDT

PHOENIX, AZ--(Marketwired - Aug 16, 2017) - Corix Bioscience Inc. (OTCQB: CXBS), a next generation tissue cell culture to pharmaceutical grade cannabinoid oil (CBD) manufacturer, announced today that it has signed an agreement with Positively Green Organics LLC. for the resale of up to 22,000 pounds of industrial hemp per month.




Hemostemix Announces Updates on Rights Offering

Tue, 15 Aug 2017 21:24:16 EDT

BLACKFALDS, ALBERTA--(Marketwired - Aug. 15, 2017) -




Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock

Tue, 15 Aug 2017 16:01:00 EDT

BERKELEY, CA--(Marketwired - August 15, 2017) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Dynavax at a price to the public of $15.00 per share. The net proceeds to Dynavax from this offering were approximately $80.8 million, after deducting the underwriting discount and other estimated offering expenses payable by Dynavax. Dynavax anticipates using the net proceeds from the proposed offering to fund activities associated with preparing for the anticipated U.S. commercial launch of HEPLISAV-BT [Hepatitis B Vaccine (Recombinant), Adjuvanted], should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support continuing the clinical development of its lead investigational cancer immunotherapeutic product candidates, SD-101 and DV281, continuing research and development activities, and for other general corporate purposes, including working capital.




Cosmos Holdings, Inc. Announces Second Quarter 2017 Results

Tue, 15 Aug 2017 10:19:44 EDT

Revenue Improved 539% and Gross Profit Improved 487% compared to the three months ended June 30, 2016




Zynerba Failure Highlights the Need for Expertise, Broader Portfolios -- SECFilings.com

Tue, 15 Aug 2017 09:00:00 EDT

REDONDO BEACH, CA--(Marketwired - Aug 15, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc.'s. (OTCQB: AXIM) clinical progress and broad portfolio in light of Zynerba's recent Phase II cannabidiol (CBD) gel patch failure.




American Cannabis Company, Inc. Announces It Has Secured A Contract With A New Client In California

Tue, 15 Aug 2017 08:30:00 EDT

DENVER, CO--(Marketwired - Aug 15, 2017) - American Cannabis Company, Inc. (OTCQB: AMMJ) ("ACC"), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced it has secured a client in the state of California. This client seeks to acquire a license that will permit them to dispense medical cannabis to patients. ACC has been contracted to complete operational planning activities, to provide conceptual design work for a retail dispensary location, to assist with 2017 city permitting, and to help with 2018 state application completion. Upon the client being awarded a city permit, ACC will be further retained in the dispensary deployment process where the consulting firm will provide facility staffing solutions, a customized set of operational workflow procedures, and remote operational monitoring support. ACC expects to leverage this contract to secure additional revenues through long-term consulting agreements and future sales of ancillary products, as this client is looking to seek licensure for the California recreational/adult-use cannabis program in the near future.




Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection

Tue, 15 Aug 2017 08:30:00 EDT

ATLANTA, GA and BOTHELL, WA--(Marketwired - Aug 15, 2017) - Cocrystal Pharma, Inc. (OTCQB: COCP), a clinical stage biopharmaceutical company focused on developing innovative antiviral therapeutics, today announced the successful completion and positive data from the Phase 1a/1b study for its lead broad spectrum compound, CC-31244, in healthy volunteers and in hepatitis C virus (HCV)-infected individuals. CC-31244 is a broad-spectrum, potent NS5B non-nucleoside inhibitor (NNI) of HCV replication with a high barrier to resistance.




Pressure BioSciences, Inc. to Discuss Second Quarter 2017 Financial Results and Provide Business Update

Tue, 15 Aug 2017 08:15:00 EDT

SOUTH EASTON, MA--(Marketwired - Aug 15, 2017) -  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2017 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay approximately one day after the call (by telephone or via a link on the Company's website). 




Akers Biosciences Announces Q2 2017 Earnings

Tue, 15 Aug 2017 07:00:00 EDT

Total Revenues for Q2 Up 25%




Opthea Presents Additional Positive Data from OPT-302 Phase 1/2a Wet AMD Trial at ASRS Meeting

Tue, 15 Aug 2017 05:30:00 EDT

MELBOURNE, AUSTRALIA--(Marketwired - Aug 15, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced further positive results from its Phase 1/2a clinical trial of OPT-302, a novel VEGF-C/D 'Trap' therapy for wet age-related macular degeneration (wet AMD). 




The Most Popular Phase of Product Development for Starting Medical Publications Activities

Mon, 14 Aug 2017 20:42:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - August 14, 2017) - A new study by business intelligence provider Cutting Edge Information found that the highest percentage of surveyed life science teams (30%) delay medical publications activities until products enter the registration and launch phase of product development.




Acasti Pharma Reports First Quarter FY 2018 Financial Results

Mon, 14 Aug 2017 17:30:00 EDT

LAVAL, QUÉBEC--(Marketwired - Aug. 14, 2017) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced its operating and financial results for the quarter ended June 30, 2017, which is the first quarter of Acasti's fiscal year 2018. All amounts are in Canadian dollars.




SANUWAVE Health Reports Second Quarter Financial Results and Provides a Business Update

Mon, 14 Aug 2017 17:00:00 EDT

SUWANEE, GA--(Marketwired - Aug 14, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV), today reported financial results for the three and six months ended June 30, 2017 and provided a business update. The Company will host a conference call at 10:30AM Eastern Time on Tuesday, August 15, 2017. 




VistaGen Therapeutics Reports First Fiscal Quarter 2018 Financial Results and Provides Business Update

Mon, 14 Aug 2017 16:05:00 EDT

SOUTH SAN FRANCISCO, CA--(Marketwired - August 14, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported its financial results for its first fiscal quarter ended June 30, 2017.




Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies

Mon, 14 Aug 2017 08:00:00 EDT

- COTI-2 safe and well-tolerated at doses up to 1.7 mg/kg

- Company to advance into head and neck squamous cell carcinoma expansion arm




Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017

Mon, 14 Aug 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - August 14, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center ("MD Anderson"), today announced its financial and operating results for the second quarter ended June 30, 2017 and other recent developments.




Cannabis Science 2017 Black Tie Gala Event Draws Near as Cannabis Science Completes Major Milestones and Operational Goals

Fri, 11 Aug 2017 14:36:42 EDT

IRVINE, CA--(Marketwired - Aug 11, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that the Company has met most of our key strategic goals for 2017, and plans are well underway for the 2017 Cannabis Science Black Tie Gala. The Gala, scheduled for the 4th quarter of this year, will be an opportunity for Cannabis Science to demonstrate the Company's appreciation for its shareholders, and to present shareholders and stakeholders an overview of Cannabis Science's many upcoming and exciting initiatives. The venue for the Gala will be in the Beverly Hills/Hollywood area of Los Angeles, CA, and will be announced shortly.




World-Class Medical Affairs: The Top 3 Changes Thought Leaders Want from Interactions with MSLs

Fri, 11 Aug 2017 10:12:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - August 11, 2017) - New industry research on global medical affairs teams found that the top three changes key opinion leaders (KOLs) desire from medical science liaisons (MSLs) are knowing the right person to contact, better communication and having fewer contact points.




SANUWAVE Health to Hold Second Quarter 2017 Financial Results and Business Update Call on Tuesday, August 15, 2017

Fri, 11 Aug 2017 09:00:00 EDT

SUWANEE, GA--(Marketwired - Aug 11, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) announced today that the Company will release financial results for the second quarter ended June 30, 2017 on August 14, 2017.




CURE Pharma Could Take Over Where Zynerba Fell Short -- CFN Media

Fri, 11 Aug 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Aug 11, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing CURE Pharmaceutical Holding Corp.(OTCQB: CURR) and its development of an oral thin film drug delivery solution that could succeed where Zynerba Pharmaceuticals' cannabidiol gel system recently failed to meet clinical endpoints.




Dewmar International BMC, Inc. (DEWM) Announces Investment in New West Genetics, Better Than Expected Progress on the Genetic Engineering of the Hemp Plant

Fri, 11 Aug 2017 08:02:53 EDT

Company Formally Announces Trials at University of Kentucky, Purdue University and the University of Nevada, Reno




Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results

Fri, 11 Aug 2017 07:00:00 EDT

Clinical responses observed in Phase 1 trial of TTI-621; Scope of trial expanded, including dose-intensification strategy; $39 million capital raise; cash and marketable securities of $72.6 million at June 30; Guidance provided on small molecule program




Corix Bioscience Announces New Tissue Culture and Research Lab

Fri, 11 Aug 2017 07:00:00 EDT

PHOENIX, AZ--(Marketwired - Aug 11, 2017) -  Corix Bioscience Inc. (OTCQB: CXBS), a next generation tissue cell culture to pharmaceutical grade cannabinoid oil (CBD) manufacturer, announces that they will move their tissue cell culture and research divisions into a new 10,122 square foot laboratory in Carson City, Nevada on a three-year lease. The lease commenced on August 1st.




IntelGenx Reports Second Quarter 2017 Financial Results

Thu, 10 Aug 2017 16:01:00 EDT

SAINT LAURENT, QUEBEC--(Marketwired - Aug. 10, 2017) - IntelGenx Technologies Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the second quarter ended June 30, 2017. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.




Pieris Pharmaceuticals Appoints Allan Reine, M.D., as Chief Financial Officer

Thu, 10 Aug 2017 08:00:00 EDT

BOSTON, MA--(Marketwired - August 10, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced that it has appointed Allan Reine as Senior Vice President and Chief Financial Officer, effective yesterday, August 9, 2017. Dr. Reine is an accomplished healthcare investor and brings to Pieris a wealth of capital markets experience, a deep biotech background, and a strong scientific acumen.




ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation, New Webinar Hosted by Xtalks

Thu, 10 Aug 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - August 10, 2017) - In 2016, significant revisions were made to the quality management standard ISO 13485, an internationally recognized standard for all medical device manufacturers. The updated changes to ISO 13485 -- the first since 2003 -- demonstrate the increasing Quality System requirements for the global medical device industry and how organizations must adhere to the forthcoming and revised standard.